Evidence map›Paper›PMID 41299103›Full record

ReviewDiscover oncology2025

Natural products as therapeutic interventions for inflammation-mediated cancer.

Srabaita Roy, Ranjit Shaw, Akanksha Pandey, Surendra Kumar Trigun

Abstract readReview
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Srabaita Roy *Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, 221005, India.
Ranjit Shaw *Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, 221005, India.
Akanksha PandeyDepartment of Zoology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, 221005, India.
Surendra Kumar TrigunDepartment of Zoology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, 221005, India. sktrigun@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation serves as the body's immune response mechanism against noxious irritants, ranging from removing factors causing injury to regenerating damaged tissue. Chronic inflammation, in particular, has emerged as a crucial contributor to both the development of cancer and its spread through a variety of mechanisms. This phenomenon is referred to as inflammation-induced tumorigenesis. Differing from other forms of inflammation that typically precede tumor formation, 'cancer-elicited inflammation (CEI)' is induced following the initiation of a tumor. Beyond the cell-autonomous effects observed in cancer cells, the activation of several oncogenes, including KRAS and MYC, coupled with the rendering of tumor suppressors, for instance, TP53 inactive, triggers programs at the transcription level that culminate in the formation of a tumor-encouraging microenvironment. This is accomplished by the overproduction of chemokines and pro-inflammatory cytokines, immune cell recruitment, and the initiation of angiogenesis. Although it is critical to comprehend the mechanisms by which inflammation aids in the development of cancer, the impact that tumors themselves have on the immune system must be considered because these effects have significant repercussions for the therapy and prevention of cancer. This comprehensive review primarily centers on various inflammatory pathways that have been influenced by cancer and have, in turn, influenced cancer progression. Additionally, we delve deeply into the intricate mechanisms through which specific natural products exert regulatory control over the complex molecular foundations that drive their robust anti-inflammatory and anti-cancer effects.

Indexed as

Cancer-induced inflammationInflammationInflammation-induced tumorigenesisNatural products.Tumor microenvironment

Identifiers

PMID41299103
PMCPMC12748368

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.